BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Add as a preferred source on Google
MOORESTOWN, N.J., March 13, 2018 -- Tabula Rasa HealthCare, Inc., (“TRHC”) (NASDAQ:TRHC) announced today that Chief Pharmacotherapy Officer Robert L. Alesiani, PharmD, BCGP, has been named the 2018 Hugo H. Schaefer Award winner by the American Pharmacists Association (APhA).
The APhA Board of Trustees selected Dr. Alesiani for this award based on his outstanding contributions to the APhA, the profession of pharmacy, and society. The awards and honors program at APhA is the most comprehensive and prestigious within the profession.
“It is truly an honor to be chosen by APhA for the Hugo H. Schaefer Award,” said Dr. Alesiani. “I look forward to continuing to improve patients’ lives, to help to hone the skills of our next generation of clinicians, and to make a positive impact in the profession. The future of pharmacy is bright!”
As Chief Pharmacotherapy Officer, Dr. Alesiani leads the Clinical Team at CareKinesis, a Tabula Rasa HealthCare company. He is one of the first clinical pharmacists in the U.S. with expertise to provide precision medicine, in particular, pharmacogenomic testing coordination and translation for people on high-risk medications. A Board-Certified Geriatric Pharmacist (BCGP), he has extensive knowledge in the field of geriatric pharmaceutical care, and he has guided his entire team of eligible pharmacists to 100% BCGP certification.
“Dr. Alesiani and I have worked together for decades,” stated Calvin H. Knowlton, PhD, Chairman, CEO and Founder of Tabula Rasa HealthCare. “Bob always has been in the vanguard of pharmacy and pharmaceutical care. He has a tremendous knowledge and experience in hospice and palliative care. He endlessly dedicates himself to bettering society through his practice. I believe he is more than deserving of this award.”
The award will be presented to Dr. Alesiani at the APhA Annual Meeting and Exposition in Nashville, Tennessee, March 16-19, 2018.
Dr. Alesiani received a BS in Marine Sciences from The Richard Stockton University (1979) in New Jersey, a BPharm from the University of the Sciences in Philadelphia (1987) and his PharmD from the University of Florida (2005), where he graduated cum laude and received the Outstanding Graduating Clinician Award. He returned in 2016 to complete a certification in Pharmacogenomic Translation and Application.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, visit: www.TRHC.com.
Contact
Dianne Semingson
[email protected]
T: 215-870-0829
